Benjamin G Vincent
Overview
Explore the profile of Benjamin G Vincent including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
7623
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yazdani A, Lenz H, Pillonetto G, Mendez-Giraldez R, Yazdani A, Sanoff H, et al.
Commun Med (Lond)
. 2025 Jan;
5(1):9.
PMID: 39779996
Background: Gene signatures derived from transcriptomic-causal networks offer potential for tailoring clinical care in cancer treatment by identifying predictive and prognostic biomarkers. This study aimed to uncover such signatures in...
2.
Beckabir W, Zhou M, Lee J, Vensko S, Woodcock M, Wang H, et al.
Nat Commun
. 2024 May;
15(1):4448.
PMID: 38789460
Neoadjuvant cisplatin-based chemotherapy is standard of care for muscle-invasive bladder cancer (MIBC). Immune checkpoint inhibition (ICI) alone, and ICI in combination with chemotherapy, have demonstrated promising pathologic response (<pT2) in...
3.
Ricketts C, de Cubas A, Fan H, Smith C, Lang M, Reznik E, et al.
Cell Rep
. 2024 Apr;
43(4):113063.
PMID: 38578829
No abstract available.
4.
Grover N, Hucks G, Riches M, Ivanova A, Moore D, Shea T, et al.
Lancet Haematol
. 2024 Mar;
11(5):e358-e367.
PMID: 38555923
Background: Chimeric antigen receptor (CAR) T cells targeting CD30 are safe and have promising activity when preceded by lymphodepleting chemotherapy. We aimed to determine the safety of anti-CD30 CAR T...
5.
Mason M, Lapuente-Santana O, Halkola A, Wang W, Mall R, Xiao X, et al.
J Transl Med
. 2024 Feb;
22(1):190.
PMID: 38383458
Background: Predictive biomarkers of immune checkpoint inhibitor (ICI) efficacy are currently lacking for non-small cell lung cancer (NSCLC). Here, we describe the results from the Anti-PD-1 Response Prediction DREAM Challenge,...
6.
Di Modugno F, Di Carlo A, Spada S, Palermo B, DAmbrosio L, DAndrea D, et al.
EBioMedicine
. 2024 Feb;
101:105003.
PMID: 38340557
Background: Tertiary Lymphoid Structures (TLS) correlate with positive outcomes in patients with NSCLC and the efficacy of immune checkpoint blockade (ICB) in cancer. The actin regulatory protein hMENA undergoes tissue-specific...
7.
Lee J, Karthikeyan D, Fini M, Vincent B, Rubinsteyn A
Brief Bioinform
. 2024 Jan;
25(1).
PMID: 38180831
The enzyme-linked immunosorbent spot (ELISpot) assay is a powerful in vitro immunoassay that enables cost-effective quantification of antigen-specific T-cell reactivity. It is used widely in the context of cancer and...
8.
Yazdani A, Lenz H, Pillonetto G, Mendez-Giraldez R, Yazdani A, Sanof H, et al.
Res Sq
. 2024 Jan;
PMID: 38168324
Predictive and prognostic gene signatures derived from interconnectivity among genes can tailor clinical care to patients in cancer treatment. We identified gene interconnectivity as the transcriptomic-causal network by integrating germline...
9.
Beckabir W, Wobker S, Damrauer J, Midkiff B, De la Cruz G, Makarov V, et al.
Eur Urol
. 2023 Dec;
85(3):242-253.
PMID: 38092611
Background: Platinum-based neoadjuvant chemotherapy (NAC) is standard for patients with muscle-invasive bladder cancer (MIBC). Pathologic response (complete: ypT0N0 and partial: <ypT2N0) to NAC is associated with improved survival with ypT0N0...
10.
Sponaugle A, Weideman A, Ranek J, Atassi G, Kuruc J, Adimora A, et al.
Cell Rep Med
. 2023 Nov;
4(11):101268.
PMID: 37949070
In people with HIV (PWH), the post-antiretroviral therapy (ART) window is critical for immune restoration and HIV reservoir stabilization. We employ deep immune profiling and T cell receptor (TCR) sequencing...